Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

U.S. Stem Cell Inc (USRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
World Bodybuilding Expert Interviews USRM Chief Science Officer At Paleo F(X) Conference

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science...

USRM : 0.0330 (-0.90%)
USRM Chief Science Officer, Dr. Kristin Comella, Featured on Health Boot Camps' Webinar

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer,...

USRM : 0.0330 (-0.90%)
U.S. Department of Justice Files Lawsuit at Request of FDA to Stop U.S. Stem Cell Clinic from Performing Autologous Stem Cell Procedure

SUNRISE, Fla. , May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine...

USRM : 0.0330 (-0.90%)
U.S. Stem Cell Reports First Quarter Results

SUNRISE, Fla. , May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0330 (-0.90%)
U.S. Stem Cell Reports First Quarter Results

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced first quarter results for 2018....

USRM : 0.0330 (-0.90%)
USRM Chief Science Officer to Host Webinar on Autologous Stem Cell Therapy

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0330 (-0.90%)
USRM Chief Science Officer Featured in Live Interview for Biohacker Summit in Helsinki

MIAMI , May 3, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, announced...

USRM : 0.0330 (-0.90%)
Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced sales figures for 2016 and 2017...

USRM : 0.0330 (-0.90%)
USRM Announces 2017 Financial Results

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today filed a Form 10-K reporting year-end numbers...

USRM : 0.0330 (-0.90%)
Newest Clinic Opens Today at The Villages in Central Florida

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening its first USRM clinic...

USRM : 0.0330 (-0.90%)
USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem Cells

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific...

USRM : 0.0330 (-0.90%)
USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem Cells

SUNRISE, Fla. , March 21, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0330 (-0.90%)
USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas

SUNRISE, Fla. , March 20, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0330 (-0.90%)
USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, is pleased to announce its Chief Science Officer,...

USRM : 0.0330 (-0.90%)
New Research: Key Drivers of Growth for Bioheart and Elite Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production

NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Bioheart Inc. (OTCQB: USRM) and Elite Pharmaceuticals Inc. (OTCQB:...

ELTP : 0.0850 (-1.16%)
USRM : 0.0330 (-0.90%)
USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, announces our participation in this year's fourth...

USRM : 0.0330 (-0.90%)
USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference

SUNRISE, Fla. , Feb. 28, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0330 (-0.90%)
USRM Posts Live Webinar with World Renowned Biohacker

SUNRISE, Fla. , Feb. 20, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0330 (-0.90%)
USRM CSO to Host Live Stem Cell Info Webinar with World Renowned Biohacker

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0330 (-0.90%)
USRM Successfully Launches Stem Cell Webinar Series

Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0330 (-0.90%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU -0.23 , ABMD -0.18 , AAXN +0.93 , NSP -0.05 , ERI +0.50
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures ended the Friday session with gains of 1 to 2 3/4 cents in the front months. July was up 3 1/2 cents on the week. CFTC data showed speculators adding 8,298 contracts to their net long position in corn futures and options to 199,970 in th...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar